AU2002211370A1 - Inhibition of tgf-beta and uses thereof - Google Patents

Inhibition of tgf-beta and uses thereof

Info

Publication number
AU2002211370A1
AU2002211370A1 AU2002211370A AU1137002A AU2002211370A1 AU 2002211370 A1 AU2002211370 A1 AU 2002211370A1 AU 2002211370 A AU2002211370 A AU 2002211370A AU 1137002 A AU1137002 A AU 1137002A AU 2002211370 A1 AU2002211370 A1 AU 2002211370A1
Authority
AU
Australia
Prior art keywords
tgf
inhibition
beta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002211370A
Other languages
English (en)
Inventor
James M Mason
Siamak Tabibzadeh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
North Shore Long Island Jewish Research Institute
Original Assignee
North Shore Long Island Jewish Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by North Shore Long Island Jewish Research Institute filed Critical North Shore Long Island Jewish Research Institute
Publication of AU2002211370A1 publication Critical patent/AU2002211370A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2002211370A 2000-10-05 2001-10-03 Inhibition of tgf-beta and uses thereof Abandoned AU2002211370A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/679,971 US6649588B1 (en) 2000-10-05 2000-10-05 Inhibition of TGF-β and uses thereof
US09/679,971 2000-10-05
PCT/US2001/030872 WO2002029105A1 (fr) 2000-10-05 2001-10-03 Inhibition du tgf-$g(b) et utilisations associees

Publications (1)

Publication Number Publication Date
AU2002211370A1 true AU2002211370A1 (en) 2002-04-15

Family

ID=24729125

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002211370A Abandoned AU2002211370A1 (en) 2000-10-05 2001-10-03 Inhibition of tgf-beta and uses thereof

Country Status (3)

Country Link
US (1) US6649588B1 (fr)
AU (1) AU2002211370A1 (fr)
WO (1) WO2002029105A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6683156B1 (en) 1996-08-27 2004-01-27 University Of South Florida Method for diagnosing selected adenocarcinomas
US6294662B1 (en) 1996-08-27 2001-09-25 University Of South Florida Nucleic acids encoding an endometrial bleeding associated factor (ebaf)
US8106001B2 (en) * 1996-08-27 2012-01-31 University Of South Florida Diagnostic markers of human female infertility
US7211644B1 (en) * 1996-08-27 2007-05-01 University Of South Florida Diagnostic markers of human female infertility
US20060099576A1 (en) * 2000-12-14 2006-05-11 Siamak Tabibzadeh Method for diagnosing a pre-neoplastic or neoplastic lesion in transitional epithelial cells
AU2003297460A1 (en) * 2002-12-19 2004-07-14 Scios, Inc. TREATMENT OF OBESITY AND ASSOCIATED CONDITIONS WITH TGF-Beta INHIBITORS
WO2004108157A2 (fr) * 2003-06-02 2004-12-16 Wyeth Methodes de traitement et de prevention des troubles neuromusculaires
US20090042780A1 (en) * 2004-05-20 2009-02-12 Acceleron Pharma Inc Modified TGF-Beta Superfamily Polypeptides and Related Methods
US7612040B2 (en) * 2005-07-01 2009-11-03 Acceleron Pharma Inc. Lefty polypeptides and derivatives thereof
US20090186076A1 (en) * 2006-02-01 2009-07-23 Kazunori Kataoka Combined Use of TGF-Beta Signaling Inhibitor and Antitumor Agent
US20100105610A1 (en) * 2006-07-28 2010-04-29 Children's Memorial Hospital Methods of Inhibiting Tumor Cell Aggressiveness Using the Microenvironment of Human Embryonic Stem Cells
US8106004B2 (en) * 2006-07-28 2012-01-31 Children's Memorial Hospital Methods of inhibiting tumor cell aggressiveness using the microenvironment of human embryonic stem cells
US8946201B2 (en) * 2007-08-27 2015-02-03 Saint Louis University Methods for inhibiting TGF-β
EP2341913B1 (fr) * 2008-09-16 2014-11-19 Saint Louis University Procédé d'amélioration de signalisation tgf-bêta
EP3898663A4 (fr) * 2018-12-20 2022-10-12 Chong Kun Dang Pharmaceutical Corp. Protéine de fusion comprenant des variants de protéine lefty a humaine et utilisation associée

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2404695A (en) 1994-05-04 1995-11-29 Mount Sinai Hospital Corporation Modulators of cytokines of the tgf-beta superfamily and methods for assaying for same
US5916751A (en) 1996-08-27 1999-06-29 University Of South Florida Method for the diagnosis of selected adenocarcinomas

Also Published As

Publication number Publication date
US6649588B1 (en) 2003-11-18
WO2002029105A1 (fr) 2002-04-11
WO2002029105A9 (fr) 2003-02-13

Similar Documents

Publication Publication Date Title
AU2001265008A1 (en) Caspase inhibitors and uses thereof
AU2001294814A1 (en) Pumpcn compositions and uses thereof
AU2002235128A1 (en) Expression miniarrays and uses thereof
AU2002225954A1 (en) Dipeptidylpeptidases and methods of use
AU2002305523A1 (en) Dioxanes and uses thereof
AU2002211370A1 (en) Inhibition of tgf-beta and uses thereof
AU2002211717A1 (en) Stresscopins and their uses
AU2002216649A1 (en) Benzoxazole lpaat- beta inhibitors and uses thereof
AU2002231206A1 (en) Treatment of depression
AU2001288682A1 (en) Inhibition of cmv infection and dissemination
AU2001292936A1 (en) Octahydro-indolizines and quinolizines and hexahydro-pyrrolizines
AU2002219900A1 (en) Minimal identification of features
AU2002211621A1 (en) Tricyclic compounds and uses thereof
AU2001232809A1 (en) Gyrase inhibitors and uses thereof
AU2001295185A1 (en) Multiplexing-interleaving and demultiplexing-deinterleaving
AU2002214189A1 (en) Methods of identifying inhibitory compounds and uses thereof
AU3732500A (en) Beclin and uses thereof
AU2001264863A1 (en) Preparation of fagopyritols and uses therefor
AU2001264273A1 (en) Amide compounds and use thereof
AU4432001A (en) Trityl-type compounds and their use
AU2001252062A1 (en) Steatosis-modulating factors and uses thereof
AU2002222125A1 (en) Prevention and treatment of tachyphylactic response
AU2001272490A1 (en) Use of galiella lactone
AU4064100A (en) P38mapk inhibitor and uses thereof
AU2001258330A1 (en) New uses of imidazolylmethyl-pyridines